» Articles » PMID: 28652417

K- Mutations As the Earliest Driving Force in a Subset of Colorectal Carcinomas

Overview
Journal In Vivo
Specialty Oncology
Date 2017 Jun 28
PMID 28652417
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

K-ras oncogene is a key factor in colorectal cancer. Based on published and our data we propose that K-ras could be the oncogene responsible for the inactivation of the tumor-suppressor gene APC, currently considered as the initial step in colorectal tumorigenesis. K-ras fulfills the criteria of the oncogene-induced DNA damage model, as it can provoke well-established causes for inactivating tumor-suppressors, i.e. DNA double-strand breaks (causing allele deletion) and ROS production (responsible for point mutation). The model we propose is a variation of the currently existing model and hypothesizes that, in a subgroup of colorectal carcinomas, K-ras mutation may precede APC inactivation, representing the earliest driving force and, probably, an early biomarker of colorectal carcinogenesis. This observation is clinically useful, since it may modify the preventive colorectal cancer strategy, restricting numerically patients undergoing colonoscopies to those bearing K-ras mutation in their colorectum, either in benign polyps or the normal accompanying mucosa.

Citing Articles

DNA signature and occult blood in stool led to diagnosis of an early-onset metastatic rectal cancer in a young pregnant woman: a case report.

van Helden J, Eidens M, Fuhrlander J, Weiskirchen R, Ogreid D J Gastrointest Oncol. 2024; 15(4):1957-1961.

PMID: 39279969 PMC: 11399848. DOI: 10.21037/jgo-24-136.


New Perspectives in Colorectal Cancers Treatment, the Role of MicroRNAs.

Belova V, Spirina L, Avgustinovich A, Afanasev S, Volkov M, Azovsky D Curr Drug Targets. 2024; 25(11):715-723.

PMID: 39051587 DOI: 10.2174/0113894501304351240703113651.


Fucoxanthin Inhibits Development of Sigmoid Colorectal Cancer in a PDX Model With Alterations of Growth, Adhesion, and Cell Cycle Signals.

Terasaki M, Tsuruoka K, Tanaka T, Maeda H, Shibata M, Miyashita K Cancer Genomics Proteomics. 2023; 20(6suppl):686-705.

PMID: 38035706 PMC: 10687734. DOI: 10.21873/cgp.20416.


Is serum thymidine kinase 1 a prognostic biomarker in primary tumor location of colorectal carcinomas?.

Fang Y, Skog S, Ou Q, Chen Z, Liu S, Hei A Discov Oncol. 2023; 14(1):21.

PMID: 36800051 PMC: 9938097. DOI: 10.1007/s12672-023-00614-5.


Dual Role of Reactive Oxygen Species and their Application in Cancer Therapy.

Huang R, Chen H, Liang J, Li Y, Yang J, Luo C J Cancer. 2021; 12(18):5543-5561.

PMID: 34405016 PMC: 8364652. DOI: 10.7150/jca.54699.


References
1.
Zeki S, Graham T, Wright N . Stem cells and their implications for colorectal cancer. Nat Rev Gastroenterol Hepatol. 2011; 8(2):90-100. DOI: 10.1038/nrgastro.2010.211. View

2.
Leslie A, Carey F, Pratt N, Steele R . The colorectal adenoma-carcinoma sequence. Br J Surg. 2002; 89(7):845-60. DOI: 10.1046/j.1365-2168.2002.02120.x. View

3.
Feng Y, Bommer G, Zhao J, Green M, Sands E, Zhai Y . Mutant KRAS promotes hyperplasia and alters differentiation in the colon epithelium but does not expand the presumptive stem cell pool. Gastroenterology. 2011; 141(3):1003-1013.e1-10. PMC: 3163826. DOI: 10.1053/j.gastro.2011.05.007. View

4.
Carethers J, Jung B . Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. Gastroenterology. 2015; 149(5):1177-1190.e3. PMC: 4589489. DOI: 10.1053/j.gastro.2015.06.047. View

5.
Langner C . Serrated and non-serrated precursor lesions of colorectal cancer. Dig Dis. 2014; 33(1):28-37. DOI: 10.1159/000366032. View